Tvardi Posts Q2 Net Income Turnaround

Tvardi Therapeutics (NASDAQ:TVRD) reported mixed Q2 2025 results, with a GAAP EPS loss of $(1.00) significantly missing analyst estimates due to higher operating costs, including merger-related fees. While GAAP net income turned positive to $4.2 million, this was driven by a non-operating gain from a convertible note remeasurement rather than core business performance. The company's cash position increased to $41.0 million following its merger with Cara Therapeutics, extending its funding runway into Q4 2026. Operationally, Tvardi advanced its clinical pipeline, completing enrollment for its TTI-101 IPF Phase 2 study with top-line results expected in Q4 2025, and submitted an IND for a new candidate, TTI-109, indicating continued progress on its key drug development programs despite the financial volatility.

Analysis

Tvardi Therapeutics reported mixed Q2 2025 results, where headline financial figures were heavily distorted by its recent merger with Cara Therapeutics. The GAAP EPS of $(1.00) represented a significant 46.9% miss against analyst estimates, primarily due to a 371.2% year-over-year increase in G&A expenses which included $1.6 million in one-time merger-related fees. While GAAP net income swung to a positive $4.2 million from a $7.0 million loss a year prior, this was not driven by operational performance but by a non-recurring $12.8 million gain on the remeasurement of convertible notes. The most critical takeaway is the company's strengthened financial position; the merger bolstered the cash balance to $41.0 million, providing a sufficient funding runway into Q4 2026 and de-risking the path to key clinical milestones. This financial restructuring also eliminated $30.3 million in convertible notes and flipped stockholder equity from a deficit of $91.1 million to a surplus of $32.9 million. Operationally, the company is advancing its core value drivers, with top-line data from its Phase 2 study of TTI-101 in idiopathic pulmonary fibrosis (IPF) expected in Q4 2025, representing a major near-term catalyst. Further pipeline progress is evidenced by the ongoing enrollment in a liver cancer trial and a new IND submission for its second candidate, TTI-109.

Key Decisions for Investors

• Investors should look past the headline GAAP EPS miss, which was driven by non-recurring merger costs, and instead focus on the upcoming top-line data for TTI-101 in IPF expected in Q4 2025 as the primary near-term value driver.
• The improved balance sheet, featuring a cash runway into Q4 2026, significantly reduces the near-term financing risk and allows the company to reach its key clinical readouts without immediate dilution pressure.
• Given its pre-revenue status, the stock remains a high-risk, event-driven investment whose valuation is highly sensitive to the binary outcomes of its clinical trials over the next 6-12 months.